1. Home
  2. ESLA vs CBAT Comparison

ESLA vs CBAT Comparison

Compare ESLA & CBAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Estrella Immunopharma Inc.

ESLA

Estrella Immunopharma Inc.

HOLD

Current Price

$1.68

Market Cap

60.9M

Sector

Health Care

ML Signal

HOLD

Logo CBAK Energy Technology Inc.

CBAT

CBAK Energy Technology Inc.

HOLD

Current Price

$0.82

Market Cap

72.1M

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESLA
CBAT
Founded
2021
1999
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Industrial Machinery/Components
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
60.9M
72.1M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
ESLA
CBAT
Price
$1.68
$0.82
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$8.00
N/A
AVG Volume (30 Days)
163.3K
72.6K
Earning Date
05-26-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$195,189,306.00
Revenue This Year
N/A
$66.88
Revenue Next Year
N/A
$41.54
P/E Ratio
N/A
N/A
Revenue Growth
N/A
10.52
52 Week Low
$0.78
$0.75
52 Week High
$3.15
$1.25

Technical Indicators

Market Signals
Indicator
ESLA
CBAT
Relative Strength Index (RSI) 51.74 47.40
Support Level $1.48 $0.83
Resistance Level $2.07 $0.85
Average True Range (ATR) 0.18 0.02
MACD -0.03 0.01
Stochastic Oscillator 16.00 61.76

Price Performance

Historical Comparison
ESLA
CBAT

About ESLA Estrella Immunopharma Inc.

Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.

About CBAT CBAK Energy Technology Inc.

CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments; CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe, India, Africa, and other regions.

Share on Social Networks: